What's in Gilberto Cruz Arteaga's pipeline?

Gilberto Cruz Arteaga has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Gilberto Cruz Arteaga's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gilberto-cruz-arteaga.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Gilberto Cruz Arteaga — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gilberto Cruz Arteaga pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Azithromycin / Ribaroxaban / Paracetamol	Azithromycin / Ribaroxaban / Paracetamol	phase 3	Fixed-dose combination (macrolide antibiotic / anticoagulant / analgesic)	Bacterial 50S ribosome (azithromycin); Factor Xa (rivaroxaban); COX enzymes (paracetamol)	Infectious Disease / Cardiovascular / Pain Management
Azithromycin / Ivermectin / Ribaroxaban / Paracetamol	Azithromycin / Ivermectin / Ribaroxaban / Paracetamol	phase 3	Fixed-dose combination (antibiotic / antiparasitic / anticoagulant / analgesic)	Multiple: bacterial 50S ribosome (azithromycin), glutamate-gated chloride channels (ivermectin), Factor Xa (rivaroxaban), COX enzymes (paracetamol)	Multi-indication (Infectious Disease / Parasitology / Cardiovascular / Pain Management)

Therapeutic area mix

Infectious Disease / Cardiovascular / Pain Management · 1
Multi-indication (Infectious Disease / Parasitology / Cardiovascular / Pain Management) · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Gilberto Cruz Arteaga:

Cite this brief

Drug Landscape (2026). Gilberto Cruz Arteaga — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gilberto-cruz-arteaga. Accessed 2026-05-17.